Company intelligence / Profile preview
Azadyne
London, United Kingdomazadyne.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Azadyne’s approach has shown striking efficacy in pre-clinical studies via the TGT enzyme pathway against a range of autoimmune diseases without broad immune suppression. The technology selectively controls natural regulatory pathways to modify specific pathogenic immune populations, offering therapeutic benefit across multiple models and human samples. Effects are seen on multiple components of the autoimmune response without causing general immunosuppression. Multiple chemical series with oral bioavailability have been identified.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small moleculeRNA therapyBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Rosalind Franklin Instituteo2h discovery
Beyond the preview
Go deeper on Azadyne.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Azadyne.